Systagenix Wound Management forms new global Medical Advisory Board

Oct 13 2009

Systagenix Wound Management has announced the formation of a new global Medical Advisory Board, consisting of a group of multi-disciplinary and highly respected wound care clinicians and practitioners from North America and Europe, which will be led by Systagenix's newly appointed Medical Director, Dr Robert Snyder.

Representing major specialist organisations and thought leaders in the wound care field, the Systagenix Medical Advisory Board will meet at specific intervals to provide feedback, input and guidance on company clinical and commercial strategies and their implementation. The group represents a broad section of the wound care clinical community with multi-disciplinary backgrounds, including academic and health economic experts, practicing surgeons, and nurse specialists. As well as advising Systagenix regarding their existing portfolio, they will focus on new and emerging technologies as well as future clinical trends within wound care. They will also advise on other critical issues, such as health economics and reimbursement in order to help Systagenix meet the changing needs of the global wound care market.

In addition to clinical and new product development, working with Dr Snyder, the Systagenix Medical Advisory Board will also focus on education, including new pathways to help reach and communicate with fellow healthcare professionals on the best and most up-to-date wound care practices.

Systagenix was formed by a management buyout of the Johnson & Johnson Professional Wound Care business which had a 75 year heritage. Systagenix has very clear objectives to become the world's strongest and most admired wound care company. The new Medical Advisory Board is designed to help the company meet those objectives by better understanding the needs of the clinician and their patients.

Systagenix's CEO, Steve Atkinson comments: "Education, innovation and forward thinking are crucial in the constantly changing and evolving wound care field. We are delighted to welcome such a prestigious panel of experts under the renowned guidance of Dr Snyder, all of whom will help us define and refine our thinking for future clinical, educational and technological developments."

Dr Snyder adds: "With such a varied and experienced panel of experts, we are bound to create new and exciting opportunities to forge ahead with innovation which is specifically aimed at meeting clinician and patient needs around the world. I am delighted that the Systagenix Medical Advisory Board has been formed and I look forward to working with the group as we seek to pioneer new ideas and techniques in wound care across a number of key areas".